FeesSafety
Pluang+

Candel Therapeutics shares plunge 26% after delaying prostate cancer drug application submission.

Market News
16 Nov 2026, 21:05 WIB
GlobeNewsWire
View Source
Bearish
Candel Therapeutics shares plunge 26% after delaying prostate cancer drug application submission.

Candel Therapeutics announced a delay in submitting its biologics license application (BLA) for aglatimagene, a prostate cancer treatment, pushing the timeline to mid-2027. This unexpected delay caused the company's stock to drop 26%, disappointing investors who expected a Q4 2026 filing. The delay has triggered an investigation by Hagens Berman into whether Candel misled investors with earlier assurances about the BLA timing. The outcome could impact investor confidence and the company's future funding prospects.

Candel Therapeutics faces investor scrutiny after a surprise delay in its biologics license application. For readers following the health sector, here is Pluang's market snapshot as of Nov 17, 2026 01:41 WIB: out of 150 priced health-sector US stocks, 39 rose and 111 fell. Notable movers include DNA at USD 8.56 with a -10.87% change and a typical hold time of 10 days, ALMS at USD 5.06 with a -9.64% change and 100% sell order activity, and RXRX at USD 2.90 with a -9.11% change and 100% buy order activity.

More News

European Commission approves RASONQUE for metastatic pancreatic cancer treatment

European Commission approves RASONQUE for metastatic pancreatic cancer treatment

The European Commission has approved RASONQUE (daraxonrasib), the first broad RAS-targeted oral medicine for adults with metastatic pancreatic adenocarcinoma who have had prior systemic therapy. This approval covers patients with or without identifie...

Market News
Bullish
1 hour ago
SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE, a European leader in multi-technical services, has acquired Dutch company Duflex B.V. to enhance its industrial automation, machine building, and robotics capabilities. Duflex, with 26 employees and €8 million revenue in 2025, specializes in ta...

Company Fundamentals
Bullish
2 hours ago
Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel Développement SAS disclosed that it repurchased a total of 3,878 of its own shares between November 9 and November 13, 2026. The average purchase price during this period was approximately €34.67 per share. This buyback is part of an authorized...

Company Fundamentals
Neutral
2 hours ago
Rexel repurchases 3,878 own shares at an average price of €34.67 in early November 2026

Rexel repurchases 3,878 own shares at an average price of €34.67 in early November 2026

Rexel Développement SAS announced it bought back a total of 3,878 of its own shares between November 9 and 13, 2026, at an average price of €34.67 per share. This share repurchase is part of the authorization granted by its shareholders to operate on...

Company Fundamentals
Neutral
2 hours ago
SPIE acquires Duflex B.V. to boost industrial automation and robotics expertise in the Netherlands.

SPIE acquires Duflex B.V. to boost industrial automation and robotics expertise in the Netherlands.

SPIE, a leading European multi-technical services company, has acquired Duflex B.V., a Dutch firm specializing in industrial automation, machine construction, and robotics. This acquisition strengthens SPIE's capabilities in the industrial services v...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App